2024-01-20 18:39:00
The National Agency for the Safety of Medicines and Health Products (ANSM) reported the January 19 a supply tension on the vaccine Revaxis suspension for injection in pre-filled syringe. diphtheria, tetanus and polio vaccine (inactivated), (adsorbed) with reduced antigen content – [anatoxine diphtérique, anatoxine tétanique, virus poliomyelitique inactivé].
The Revaxis vaccine (dTP) is indicated in adults, as a booster of a previous vaccination, for the joint prevention of diphtheria, tetanus and poliomyelitis. It is appropriate to refer to the official recommendations of the vaccination schedule. Exceptionally, for booster shots in children and adolescents aged 6 and 11-13 years, this vaccine can be used in the event of a contraindication to whooping cough vaccination.
- Its distribution is limited on the private market (community pharmacies).
- DROMs and hospitals are not affected by this quota.
- Normal delivery is planned for the end of February 2024
In order to secure the situation in France as much as possible and to preserve available stocks, the sale and export of the medicine by wholesale distributors abroad is prohibited from the publication of this information sheet on our site ( application of public health law 2016-41 published in the Official Journal on January 27, 2016 and the provisions of articles L. 5121-30 and L.5124-17-3 of the Public Health Code).
This measure prohibiting sales outside the national territory, or to wholesale distributors for export, must be applied and respected until the medicine is made available normally, allowing a continuous and appropriate supply to the national market.
Source: National Agency for the Safety of Medicines and Health Products (ANSM)
1705804803
#Supply #tension #dip #vaccine..
